Navigation Links
Pharmalink AB Closes Deal With Grifols SA for the Acquisition of the Xepol(R) Programme for the Treatment of Post-Polio Syndrome
Date:6/30/2010

STOCKHOLM, June 30, 2010 /PRNewswire/ --

- Agreement Marks Milestone in Pharmalink's Corporate Development

Pharmalink AB, today announced that it has closed its agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R) programme for the treatment of post-polio syndrome (PPS). The parties had previously announced reaching an agreement whereby Grifols would acquire all know-how and global intellectual property rights related to the use of human immunoglobulin for the treatment of (PPS) - the concept at the heart of the Xepol programme.

The agreement covers acquisition of one of Pharmalink's wholly owned subsidiaries and includes inter alia US, EU and Japan patents for the treatment of PPS with immunoglobulins, a US Orphan Drug Designation (ODD) for the use of immunoglobulin for the treatment of PPS and documentation of a number of clinical studies carried out in the recent years.

Johan Haggblad, Managing director of Pharmalink AB said: "This agreement marks a significant milestone in Pharmalink's corporate development. In developing a concept originally devised by academic researchers at the Karolinska Institute and seeing it through to being acquired by a world class company we have demonstrated the considerable value creation made possible by the Pharmalink model. We are very happy to see Grifols, our long standing partner, acquire and develop the PPS indication and to have played a part in bringing forward a treatment for this underserved condition."

Grifols will develop the PPS product opportunity using the acquired assets. Pharmalink will assist in technology trans
'/>"/>

SOURCE Pharmalink AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmalink AB Strengthens its Board of Directors and Signals a Strategic Step Towards Late Phase Product Development
2. Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Pharmaxis Closes Share Purchase Plan
11. The closest look ever at native human tissue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Genome Sciences at the University of Maryland School of ... Medical Research Institute of Infectious Diseases and Northern Arizona ... their investigation into the anthrax attacks of 2001. The ... microbiology in a criminal investigation. More than 20 people ...
... package designed to minimize the potential risks of synthetic ... available to the gene synthesis industry and synthetic biology ... licensed GenoTHREAT, a software tool that helps detect the ... an open-source project by a team led by Jean ...
... new drug that will regenerate a critical enzyme in ... exposed to deadly chemical warfare agents. Christopher Hadad, ... (OSU), is leveraging Ohio Supercomputer Center (OSC) resources to ... called organophosphorus (OP) nerve agents. "This project ...
Cached Biology Technology:University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 3University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 4Open-source software designed to minimize synthetic biology risks 2OSU chemist developing solution to nerve agent exposure 2
(Date:4/21/2014)... daily pill to lower cholesterol can reduce heart attack ... inflammation could help save the vision of diabetics, scientists ... with high doses of niacin to decrease bad cholesterol ... an effective mark for these patients, said Dr. Pamela ... Georgia Regents University. , Martin is Principal Investigator ...
(Date:4/21/2014)... In recent years, there are growing studies ... for sustained-release and controlled-release of nerve growth ... by Prof. Gao Li and team from ... and Technology in China, amino-functionalized ethylenediamine-treated multi-walled ... nanotubes-nerve growth factor complexes by non-covalent grafting. ...
(Date:4/20/2014)... to treat lung, breast and pancreatic cancers also promote ... University of California, San Diego School of Medicine have ... surface of drug-resistant tumors that appears responsible for inducing ... cancer cells. , The findings, published in the ... Biology , may point to new therapeutic opportunities for ...
Breaking Biology News(10 mins):Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3Cancer stem cells linked to drug resistance 2
... Jewish Health have discovered a type of cell that may ... lupus, multiple sclerosis and rheumatoid arthritis strike women more frequently ... make autoantibodies, which bind to and attack the body,s own ... of the journal Blood , that they found higher ...
... programmed cell death - a process by which cells ... in termites. And it appears this regression may be ... defensive organs, according to Kouhei Toga and Kiyoto Maekawa ... the University of Tokyo, in Japan. Their findings have ...
... tropics make it tough for farmers to keep their crops ... seems to defy efforts to control its population. Some farmers ... the weevils but they have not been successful. Since the ... the immature stages. The sweetpotato weevil is a year round ...
Cached Biology News:B-cell discovery suggests why women suffer more autoimmune disease 2Cells die so defensive organs can live 2Biocontrol of sweetpotato weevils 2
...
... Antibody Modification Services ,,GenScript ... antibody labeling and antibody fragmentation. Labeling ... signals for visualization and quantitation of ... it is preferable to use only ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: